Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for MRUS

Stock Name	Merus BV
Ticker	MRUS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	NL0011606264

Show aggregate MRUS holdings

News associated with MRUS

Merus N.V. (NASDAQ:MRUS) Receives Average Recommendation of “Buy” from Analysts: Merus N.V. (NASDAQ:MRUS – Get Free Report) has received an average recommendation of “Buy” from the twelve research firms that are covering the firm, Marketbeat.com reports. Eleven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that […] - 2025-09-04 03:06:58
Merus (NASDAQ:MRUS) Coverage Initiated at Alliance Global Partners: Research analysts at Alliance Global Partners started coverage on shares of Merus (NASDAQ:MRUS – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $90.00 price target on the biotechnology company’s stock. Alliance Global Partners’ target price suggests a potential upside of 34.61% from the […] - 2025-08-27 02:30:45
Leerink Partnrs Estimates Merus’ Q3 Earnings (NASDAQ:MRUS): Merus N.V. (NASDAQ:MRUS – Free Report) – Analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for Merus in a report issued on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of ($1.50) for the quarter, down from their prior estimate of ($1.32). […] - 2025-08-12 02:46:48
Merus (NASDAQ:MRUS) Downgraded to Sell Rating by Wall Street Zen: Merus (NASDAQ:MRUS – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday. A number of other research analysts have also issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $75.00 […] - 2025-07-22 02:07:06
Wall Street Zen Upgrades Merus (NASDAQ:MRUS) to “Hold”: Merus (NASDAQ:MRUS – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. A number of other brokerages have also issued reports on MRUS. William Blair reaffirmed an “outperform” rating on shares of Merus in a research report on […] - 2025-07-14 03:40:50
Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock: Merus N.V. (NASDAQ:MRUS – Get Free Report) COO Peter B. Silverman sold 34,000 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a legal filing with the SEC, which is accessible […] - 2025-06-27 05:10:52
Merus N.V. (NASDAQ:MRUS) Receives $84.64 Average Price Target from Brokerages: Merus N.V. (NASDAQ:MRUS – Get Free Report) has been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat reports. Twelve equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price […] - 2025-06-24 02:36:57
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Merus (NASDAQ:MRUS – Free Report) by 17.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,744 shares of the biotechnology company’s stock after purchasing an additional 14,544 shares […] - 2025-06-05 05:13:00
Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln: (RTTNews) - Merus N.V. (MRUS), a Dutch oncology company developing multispecific antibodies and antibody drug conjugates, Wednesday announced the pricing of an underwritten public offering of around 5.26 million shares, at a price of $57.00 per share. The gross proceeds from the - 2025-06-04 01:56:43
Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares: Merus N.V. announced a $300 million public offering of 5.26 million common shares to fund clinical development and research. - 2025-06-04 01:20:22
Analysts Anticipate 25% Gains Ahead For The Holdings of FHLC: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:03:59
Merus (NASDAQ:MRUS) Earns Buy Rating from Needham & Company LLC: Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside […] - 2025-05-21 03:03:18
Merus (NASDAQ:MRUS) Holdings Decreased by The Manufacturers Life Insurance Company: The Manufacturers Life Insurance Company reduced its stake in shares of Merus (NASDAQ:MRUS – Free Report) by 17.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,085 shares of the biotechnology company’s stock after selling 9,204 shares during the quarter. […] - 2025-05-12 05:36:50
Tudor Investment Corp ET AL Purchases Shares of 5,075 Merus (NASDAQ:MRUS): Tudor Investment Corp ET AL bought a new stake in Merus (NASDAQ:MRUS – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,075 shares of the biotechnology company’s stock, valued at approximately $213,000. A number of other institutional investors and hedge […] - 2025-05-11 05:44:52
Tower Research Capital LLC TRC Decreases Stock Holdings in Merus (NASDAQ:MRUS): Tower Research Capital LLC TRC decreased its stake in shares of Merus (NASDAQ:MRUS – Free Report) by 77.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,668 shares of the biotechnology company’s stock after selling 9,221 shares during the […] - 2025-05-09 05:21:09
Merus (NASDAQ:MRUS) Short Interest Update: Merus (NASDAQ:MRUS – Get Free Report) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,270,000 shares, a decrease of 15.5% from the March 31st total of 7,420,000 shares. Currently, 9.6% of the company’s shares are sold short. Based on […] - 2025-05-05 04:58:56
Merus (NASDAQ:MRUS) Earns “Outperform” Rating from William Blair: William Blair reaffirmed their outperform rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report issued on Monday morning,RTT News reports. Several other analysts have also commented on the stock. Guggenheim reissued a “buy” rating and set a $109.00 target price on shares of Merus in a research note on Friday, March 28th. […] - 2025-04-29 04:54:48
Invesco Ltd. Grows Stock Position in Merus (NASDAQ:MRUS): Invesco Ltd. lifted its holdings in Merus (NASDAQ:MRUS – Free Report) by 2.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 786,365 shares of the biotechnology company’s stock after purchasing an additional 16,712 shares during the period. Invesco Ltd. owned about 1.15% of Merus […] - 2025-04-18 05:18:50
HighTower Advisors LLC Has $337,000 Stock Position in Merus (NASDAQ:MRUS): HighTower Advisors LLC lifted its position in Merus (NASDAQ:MRUS – Free Report) by 10.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,020 shares of the biotechnology company’s stock after buying an additional 789 shares during the period. HighTower […] - 2025-04-02 04:14:47
Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS): Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a report issued on Tuesday,Benzinga reports. They presently have a $109.00 target price on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 131.91% from the company’s previous close. Other research analysts also recently […] - 2025-03-20 04:55:00
Bank of America Has Lowered Expectations for Merus (NASDAQ:MRUS) Stock Price: Merus (NASDAQ:MRUS – Get Free Report) had its target price lowered by analysts at Bank of America from $73.00 to $70.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective indicates a potential upside of 47.12% from the […] - 2025-03-12 04:00:48
HC Wainwright Reaffirms “Buy” Rating for Merus (NASDAQ:MRUS): Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $85.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 90.41% from the stock’s previous close. […] - 2025-03-05 04:32:51
William Blair Predicts Merus’ FY2028 Earnings (NASDAQ:MRUS): Merus (NASDAQ:MRUS – Free Report) – William Blair issued their FY2028 EPS estimates for Merus in a report issued on Friday, February 28th. William Blair analyst M. Phipps expects that the biotechnology company will post earnings per share of ($3.58) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate […] - 2025-03-04 06:28:57
Merus (NASDAQ:MRUS) Given New $83.00 Price Target at Needham & Company LLC: Merus (NASDAQ:MRUS – Free Report) had its price objective lowered by Needham & Company LLC from $85.00 to $83.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also recently commented on the company. The Goldman […] - 2025-03-03 04:54:51
Merus (NASDAQ:MRUS) Shares Purchased by State of New Jersey Common Pension Fund D: State of New Jersey Common Pension Fund D grew its holdings in shares of Merus (NASDAQ:MRUS – Free Report) by 29.0% during the 4th quarter, HoldingsChannel reports. The firm owned 48,268 shares of the biotechnology company’s stock after buying an additional 10,842 shares during the period. State of New Jersey Common Pension Fund D’s holdings […] - 2025-02-24 06:42:49
Analysts Set Merus (NASDAQ:MRUS) PT at $85.92: Shares of Merus (NASDAQ:MRUS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the sixteen research firms that are covering the stock, MarketBeat reports. Fourteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […] - 2025-02-19 04:46:55
KBC Group NV Has $2.41 Million Stake in Merus (NASDAQ:MRUS): KBC Group NV raised its position in Merus (NASDAQ:MRUS – Free Report) by 4,583.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,234 shares of the biotechnology company’s stock after purchasing an additional 56,012 shares during the quarter. KBC Group NV’s holdings in […] - 2025-02-02 07:28:57

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) MRUS holdings

Date	Number of MRUS Shares Held	Base Market Value of MRUS Shares	Local Market Value of MRUS Shares	Change in MRUS Shares Held	Change in MRUS Base Value	Current Price per MRUS Share Held	Previous Price per MRUS Share Held
2025-11-11 (Tuesday)	49,021	USD 4,680,525	USD 4,680,525	0	USD 2,941	USD 95.48	USD 95.42
2025-11-10 (Monday)	49,021	USD 4,677,584	USD 4,677,584	125	USD 21,218	USD 95.42	USD 95.23
2025-11-07 (Friday)	48,896	USD 4,656,366	USD 4,656,366	0	USD 3,423	USD 95.23	USD 95.16
2025-11-06 (Thursday)	48,896	USD 4,652,943	USD 4,652,943	125	USD 10,919	USD 95.16	USD 95.18
2025-11-05 (Wednesday)	48,771	USD 4,642,024	USD 4,642,024	0	USD 6,828	USD 95.18	USD 95.04
2025-11-04 (Tuesday)	48,771	USD 4,635,196	USD 4,635,196	126	USD 24,623	USD 95.04	USD 94.78
2025-11-03 (Monday)	48,645	USD 4,610,573	USD 4,610,573	0	USD -3,892	USD 94.78	USD 94.86
2025-10-31 (Friday)	48,645	USD 4,614,465	USD 4,614,465	0	USD -9,729	USD 94.86	USD 95.06
2025-10-30 (Thursday)	48,645	USD 4,624,194	USD 4,624,194	630	USD 71,892	USD 95.06	USD 94.81
2025-10-29 (Wednesday)	48,015	USD 4,552,302	USD 4,552,302	792	USD 70,839	USD 94.81	USD 94.9
2025-10-28 (Tuesday)	47,223	USD 4,481,463	USD 4,481,463	0	USD 14,167	USD 94.9	USD 94.6
2025-10-27 (Monday)	47,223	USD 4,467,296	USD 4,467,296	0	USD -13,222	USD 94.6	USD 94.88

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MRUS by Blackrock for IE00BDZVHG35

Show aggregate share trades of MRUS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 125 95.440 95.150 95.179 USD 11,897 53.84
2025-11-06 BUY 125 95.340 95.020 95.052 USD 11,881 53.40
2025-11-04 BUY 126 95.080 94.760 94.792 USD 11,944 52.95
2025-10-30 BUY 630 95.060 94.850 94.871 USD 59,769 52.26
2025-10-29 BUY 792 94.810 95.300 95.251 USD 75,439 52.02
2025-10-22 SELL -496 94.400 94.750 94.715 USD -46,979 50.81 Loss of -21,777 on sale
2025-10-20 BUY 248 94.440 94.840 94.800 USD 23,510 50.31
2025-10-17 BUY 620 94.890 95.040 95.025 USD 58,916 50.05
2025-10-15 BUY 992 94.950 94.960 94.959 USD 94,199 49.79
2025-10-03 BUY 868 94.290 94.350 94.344 USD 81,891 49.26
2025-10-02 BUY 124 94.150 94.390 94.366 USD 11,701 49.00
2025-09-30 BUY 248 94.150 94.295 94.280 USD 23,382 48.46
2025-09-26 BUY 248 68.890 69.510 69.448 USD 17,223 48.06
2025-09-25 BUY 248 68.100 68.550 68.505 USD 16,989 47.94
2025-09-18 BUY 119 68.950 69.610 69.544 USD 8,276 47.81
2025-09-17 BUY 360 68.175 69.625 69.480 USD 25,013 47.68
2025-09-11 SELL -120 69.800 70.647 70.562 USD -8,467 47.42 Loss of -2,777 on sale
2025-09-10 BUY 240 67.130 68.960 68.777 USD 16,506 47.30
2025-07-17 SELL -240 61.440 61.530 61.521 USD -14,765 46.87 Loss of -3,516 on sale
2025-07-16 BUY 499 56.505 56.770 56.744 USD 28,315 46.81
2025-07-11 SELL -944 54.500 55.230 55.157 USD -52,068 46.64 Loss of -8,036 on sale
2025-07-02 BUY 6,490 53.330 54.180 54.095 USD 351,077 46.44
2025-06-25 BUY 236 53.880 54.630 54.555 USD 12,875 46.25
2025-06-20 BUY 1,051 53.105 53.310 53.290 USD 56,007 46.10
2025-06-11 BUY 230 55.050 57.000 56.805 USD 13,065 45.69
2025-06-10 BUY 230 56.450 57.360 57.269 USD 13,172 45.61
2025-06-04 SELL -115 57.580 58.940 58.804 USD -6,762 45.28 Loss of -1,555 on sale
2025-04-23 BUY 115 41.830 45.900 45.493 USD 5,232 45.06
2025-04-10 SELL -920 38.620 39.240 39.178 USD -36,044 45.34 Profit of 5,669 on sale
2025-04-08 SELL -115 34.890 39.490 39.030 USD -4,488 45.53 Profit of 747 on sale
2025-04-07 SELL -115 37.390 37.620 37.597 USD -4,324 45.62 Profit of 923 on sale
2025-04-04 SELL -575 38.110 40.690 40.432 USD -23,248 45.71 Profit of 3,034 on sale
2025-04-01 BUY 1,015 39.600 42.438 42.154 USD 42,787 45.82
2025-03-31 SELL -339 42.090 45.440 45.105 USD -15,291 45.86 Profit of 256 on sale
2025-03-21 BUY 1,769 47.240 48.720 48.572 USD 85,924 45.84
2025-03-14 SELL -1,712 47.100 49.250 49.035 USD -83,948 45.74 Loss of -5,638 on sale
2025-03-07 SELL -214 46.070 47.210 47.096 USD -10,079 45.61 Loss of -317 on sale
2025-03-04 SELL -107 44.640 45.280 45.216 USD -4,838 45.61 Profit of 42 on sale
2025-02-25 BUY 214 44.400 46.700 46.470 USD 9,945 45.60
2025-02-19 SELL -107 45.070 45.180 45.169 USD -4,833 45.52 Profit of 37 on sale
2025-02-13 BUY 321 40.300 41.145 41.061 USD 13,180 45.90
2025-02-12 BUY 107 40.260 40.450 40.431 USD 4,326 46.01
2025-02-11 BUY 428 40.110 40.660 40.605 USD 17,379 46.14
2024-12-30 SELL -3,670 41.890 42.385 42.335 USD -155,371 48.41 Profit of 22,283 on sale
2024-11-18 SELL -1,755 44.270 46.820 46.565 USD -81,722 52.22 Profit of 9,917 on sale
2024-11-08 SELL -117 54.500 54.900 54.860 USD -6,419 52.09 Loss of -324 on sale
2024-10-21 SELL -117 51.600 52.430 52.347 USD -6,125 0.00 Loss of -6,125 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	125	95.440	95.150	95.179	USD 11,897	53.84
2025-11-06	BUY	125	95.340	95.020	95.052	USD 11,881	53.40
2025-11-04	BUY	126	95.080	94.760	94.792	USD 11,944	52.95
2025-10-30	BUY	630	95.060	94.850	94.871	USD 59,769	52.26
2025-10-29	BUY	792	94.810	95.300	95.251	USD 75,439	52.02
2025-10-22	SELL	-496	94.400	94.750	94.715	USD -46,979	50.81 Loss of -21,777 on sale
2025-10-20	BUY	248	94.440	94.840	94.800	USD 23,510	50.31
2025-10-17	BUY	620	94.890	95.040	95.025	USD 58,916	50.05
2025-10-15	BUY	992	94.950	94.960	94.959	USD 94,199	49.79
2025-10-03	BUY	868	94.290	94.350	94.344	USD 81,891	49.26
2025-10-02	BUY	124	94.150	94.390	94.366	USD 11,701	49.00
2025-09-30	BUY	248	94.150	94.295	94.280	USD 23,382	48.46
2025-09-26	BUY	248	68.890	69.510	69.448	USD 17,223	48.06
2025-09-25	BUY	248	68.100	68.550	68.505	USD 16,989	47.94
2025-09-18	BUY	119	68.950	69.610	69.544	USD 8,276	47.81
2025-09-17	BUY	360	68.175	69.625	69.480	USD 25,013	47.68
2025-09-11	SELL	-120	69.800	70.647	70.562	USD -8,467	47.42 Loss of -2,777 on sale
2025-09-10	BUY	240	67.130	68.960	68.777	USD 16,506	47.30
2025-07-17	SELL	-240	61.440	61.530	61.521	USD -14,765	46.87 Loss of -3,516 on sale
2025-07-16	BUY	499	56.505	56.770	56.744	USD 28,315	46.81
2025-07-11	SELL	-944	54.500	55.230	55.157	USD -52,068	46.64 Loss of -8,036 on sale
2025-07-02	BUY	6,490	53.330	54.180	54.095	USD 351,077	46.44
2025-06-25	BUY	236	53.880	54.630	54.555	USD 12,875	46.25
2025-06-20	BUY	1,051	53.105	53.310	53.290	USD 56,007	46.10
2025-06-11	BUY	230	55.050	57.000	56.805	USD 13,065	45.69
2025-06-10	BUY	230	56.450	57.360	57.269	USD 13,172	45.61
2025-06-04	SELL	-115	57.580	58.940	58.804	USD -6,762	45.28 Loss of -1,555 on sale
2025-04-23	BUY	115	41.830	45.900	45.493	USD 5,232	45.06
2025-04-10	SELL	-920	38.620	39.240	39.178	USD -36,044	45.34 Profit of 5,669 on sale
2025-04-08	SELL	-115	34.890	39.490	39.030	USD -4,488	45.53 Profit of 747 on sale
2025-04-07	SELL	-115	37.390	37.620	37.597	USD -4,324	45.62 Profit of 923 on sale
2025-04-04	SELL	-575	38.110	40.690	40.432	USD -23,248	45.71 Profit of 3,034 on sale
2025-04-01	BUY	1,015	39.600	42.438	42.154	USD 42,787	45.82
2025-03-31	SELL	-339	42.090	45.440	45.105	USD -15,291	45.86 Profit of 256 on sale
2025-03-21	BUY	1,769	47.240	48.720	48.572	USD 85,924	45.84
2025-03-14	SELL	-1,712	47.100	49.250	49.035	USD -83,948	45.74 Loss of -5,638 on sale
2025-03-07	SELL	-214	46.070	47.210	47.096	USD -10,079	45.61 Loss of -317 on sale
2025-03-04	SELL	-107	44.640	45.280	45.216	USD -4,838	45.61 Profit of 42 on sale
2025-02-25	BUY	214	44.400	46.700	46.470	USD 9,945	45.60
2025-02-19	SELL	-107	45.070	45.180	45.169	USD -4,833	45.52 Profit of 37 on sale
2025-02-13	BUY	321	40.300	41.145	41.061	USD 13,180	45.90
2025-02-12	BUY	107	40.260	40.450	40.431	USD 4,326	46.01
2025-02-11	BUY	428	40.110	40.660	40.605	USD 17,379	46.14
2024-12-30	SELL	-3,670	41.890	42.385	42.335	USD -155,371	48.41 Profit of 22,283 on sale
2024-11-18	SELL	-1,755	44.270	46.820	46.565	USD -81,722	52.22 Profit of 9,917 on sale
2024-11-08	SELL	-117	54.500	54.900	54.860	USD -6,419	52.09 Loss of -324 on sale
2024-10-21	SELL	-117	51.600	52.430	52.347	USD -6,125	0.00 Loss of -6,125 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MRUS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	123,755	15,565	295,324	41.9%
2025-09-18	97,316	4,160	228,737	42.5%
2025-09-17	144,327	1,098	242,465	59.5%
2025-09-16	109,960	2,131	222,434	49.4%
2025-09-15	149,890	0	318,679	47.0%
2025-09-12	313,455	5,537	606,036	51.7%
2025-09-11	186,041	17,755	345,081	53.9%
2025-09-10	77,299	0	149,184	51.8%
2025-09-09	109,277	12,250	231,075	47.3%
2025-09-08	110,300	0	207,990	53.0%
2025-09-05	113,743	2,003	270,192	42.1%
2025-09-04	71,390	0	194,435	36.7%
2025-09-03	118,236	1,764	269,037	43.9%
2025-09-02	104,542	485	304,738	34.3%
2025-08-29	88,408	602	208,720	42.4%
2025-08-28	205,679	1,769	570,454	36.1%
2025-08-27	43,727	0	107,171	40.8%
2025-08-26	49,221	0	280,420	17.6%
2025-08-25	51,161	0	113,717	45.0%
2025-08-22	100,156	7,575	192,111	52.1%
2025-08-21	72,411	5,956	216,042	33.5%
2025-08-20	59,660	0	265,385	22.5%
2025-08-19	94,849	0	242,816	39.1%
2025-08-18	49,307	2,689	113,536	43.4%
2025-08-15	64,984	10,335	112,733	57.6%
2025-08-14	76,844	0	278,924	27.6%
2025-08-13	178,506	1,001	423,476	42.2%
2025-08-12	86,718	1,133	254,301	34.1%
2025-08-11	84,695	390	117,680	72.0%
2025-08-08	112,422	1,666	230,834	48.7%
2025-08-07	130,196	179	222,638	58.5%
2025-08-06	255,436	0	409,279	62.4%
2025-08-05	102,319	5,000	286,822	35.7%
2025-08-04	43,196	0	67,788	63.7%
2025-08-01	111,333	0	277,022	40.2%
2025-07-31	164,449	300	435,717	37.7%
2025-07-30	114,739	0	179,110	64.1%
2025-07-29	69,987	0	152,833	45.8%
2025-07-28	117,863	0	253,637	46.5%
2025-07-25	170,530	0	303,999	56.1%
2025-07-24	254,664	4,904	482,530	52.8%
2025-07-23	145,170	0	217,503	66.7%
2025-07-22	139,563	525	302,776	46.1%
2025-07-21	287,134	1,374	573,961	50.0%
2025-07-18	269,923	0	465,096	58.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE